Literature DB >> 18458955

Comparison of intraperitoneal antithrombin III and heparin in experimental peritonitis.

Sema Akman1, Mustafa Koyun, Tekinalp Gelen, Mesut Coskun.   

Abstract

The antifibrotic effect of heparin, an anticoagulant used routinely in the treatment of peritonitis, is unknown, whereas antithrombin III (AT-III) has both anticoagulant and anti-inflammatory actions. The aim of this study was to compare the antifibrotic and anti-inflammatory effects of AT-III and heparin in rats with experimentally developed peritonitis while on peritoneal dialysis (PD). Sixty-four Wistar albino rats (in four groups of 16) were used in the study. Group 1 received PD solution only, group 2 had experimentally developed peritonitis in addition to PD solution; group 3 received heparin intraperitoneally for 3 days, in addition to group 2; and group 4 received AT-III intraperitoneally for 3 days, in addition to group 2. Plasma and dialysate levels of tissue-plasminogen activator were similar in heparin and AT-III groups on both day 3 and day 14. The inflammation scores of heparin and AT-III groups were also similar in both early and late phases. The fibrosis score of the AT-III group was low compared with both peritonitis and heparin groups in the early phase (p = 0.03), though it was similar in the late phase. The effects of AT-III are comparable with that of heparin in PD peritonitis in rats with experimentally developed peritonitis while on PD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18458955     DOI: 10.1007/s00467-008-0829-7

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  16 in total

1.  Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation.

Authors:  Farhan Bazargani; Ann Albrektsson; Noushin Yahyapour; Magnus Braide
Journal:  Perit Dial Int       Date:  2005 Jul-Aug       Impact factor: 1.756

2.  Inhibitory effect of heparin and/or antithrombin III on intraperitoneal fibrin formation in continuous ambulatory peritoneal dialysis.

Authors:  T Tabata; H Shimada; M Emoto; A Morita; Y Furumitsu; J Fujita; T Inoue; T Miki; Y Nishizawa; H Morii
Journal:  Nephron       Date:  1990       Impact factor: 2.847

3.  Intraperitoneal hypercoagulation and hypofibrinolysis is present in childhood peritonitis.

Authors:  A W de Boer; M Levi; R E Reddingius; J L Willems; S van den Bosch; C H Schröder; L A Monnens
Journal:  Pediatr Nephrol       Date:  1999-05       Impact factor: 3.714

4.  Effects of intraperitoneal heparin on peritoneal transport in a chronic animal model of peritoneal dialysis.

Authors:  K Pawlaczyk; M Kuzlan-Pawlaczyk; B Anderstam; O Heimbürger; J Bergström; J Waniewski; A Breborowicz; B Lindholm
Journal:  Nephrol Dial Transplant       Date:  2001-03       Impact factor: 5.992

5.  Activity of intraperitoneal heparin during peritoneal dialysis.

Authors:  K I Furman; E D Gomperts; J Hockley
Journal:  Clin Nephrol       Date:  1978-01       Impact factor: 0.975

6.  Plasma levels and loss of antithrombin III in chronic ambulatory peritoneal dialysis and nephrotic patients.

Authors:  R Mori; L Triolo; V De Stefano; B P Giusti; P De Sole; G Leone
Journal:  Nephron       Date:  1988       Impact factor: 2.847

7.  Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients.

Authors:  Jonas Angel Sjøland; Robert Smith Pedersen; Jørgen Jespersen; Jørgen Gram
Journal:  Nephron Clin Pract       Date:  2005-04-20

8.  Protein C, protein S, and antithrombin III levels in patients on continuous ambulatory peritoneal dialysis and hemodialysis.

Authors:  K N Lai; J A Yin; P M Yuen; P K Li
Journal:  Nephron       Date:  1990       Impact factor: 2.847

9.  Is heparin therapy necessary in CAPD peritonitis?

Authors:  C Nadig; U Binswanger; A von Felten
Journal:  Perit Dial Int       Date:  1997 Sep-Oct       Impact factor: 1.756

10.  Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells.

Authors:  T Sitter; M Spannagl; H Schiffl; E Held; V W van Hinsbergh; T Kooistra
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.